Historical Stock Chart
2 Months : From Nov 2019 to Jan 2020
By Colin Kellaher
Amgen Inc. (AMGN) on Tuesday said a phase 3 study evaluating Kyprolis in combination with dexamethasone and Darzalex met its primary endpoint in patients with the blood cancer multiple myeloma.
The Thousand Oaks, Calif., biotechnology company said the study met its main endpoint of progression-free survival, resulting in a 37% reduction in the risk of disease progression or death in patients with relapsed or refractory multiple myeloma.
Amgen said the combination also showed efficacy in key secondary endpoints, including overall response rate and overall survival.
Johnson & Johnson's (JNJ) Janssen Biotech Inc. unit has an exclusive license to develop, manufacture and commercialize Darzalex under an August 2012 agreement with Danish biotechology company Genmab A/S (GMAB).
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
December 10, 2019 08:05 ET (13:05 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.